Prelude Therapeutics (PRLD) Earnings Analysis

Prelude Therapeutics (PRLD) next reports earnings on 2026-08-13, consensus EPS -0.2225 USD. Last quarter (2026-03-10) it beat with EPS -0.2 USD vs -0.33 USD est (+39.4%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -3.70.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PRLD next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.2225 USD
Revenue estimate0.00B

PRLD earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-10-0.2 USD-0.33 USD+39.4%Beat
2025-11-12-0.26 USD-0.35 USD+25.7%Beat
2025-08-14-0.41 USD-0.45 USD+8.9%Beat
2025-03-10-0.38 USD-0.49 USD+22.4%Beat
2024-08-12-0.46 USD-0.46 USD0%Beat

Beat rate: 5/5 (100%) over reported quarters with consensus data.

PRLD valuation and analyst view

Trailing P/E-3.70
Trailing EPS-0.94278 USD
Price / book5.38
Dividend yield0.00%
Market cap0.22B
Analyst consensusBuy (5 buy / 1 hold / 2 sell)
Avg price target8 USD

Related research pages

Frequently asked questions

When is Prelude Therapeutics (PRLD)'s next earnings date?

Prelude Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.2225 USD and revenue estimate of 0.00B.

Did PRLD beat earnings last quarter?

In its 2026-03-10 report, PRLD posted EPS of -0.2 USD versus a -0.33 USD estimate — a beat of 39.4%.

What is PRLD's earnings track record?

Over the last 5 reported quarters with consensus data, PRLD beat estimates 5 times (100%).

What is PRLD's current P/E ratio and EPS?

PRLD trades at a trailing P/E of -3.70 on trailing EPS of -0.9427777255547356 USD.

What do analysts rate PRLD?

Analyst consensus is "Buy" across 8 ratings (0 strong buy, 5 buy, 1 hold, 2 sell, 0 strong sell). Average 12-month price target: 8 USD.